News for Emyria Limited (EMD.AX)

Emyria Ltd has launched a second Empax clinic in Western Australia, aiming to support patients with depression and PTSD

Emyria Ltd has rolled out a Placement to raise more than $2M to expand mental health treatments at its Leederville centre

Emyria Ltd and the University of Western Australia have formed a partnership to secure global rights to a library of patented compounds

Shares in MDMA psychotherapy player Emyria (ASX:EMD) jumped 9.4% to 3.5cps on Monday following reports of 'interim' success treating patients with PTSD.

Tryptamine Therapeutics (ASX:TYP) has confirmed it's wrapped up its first-ever IV psilocin injections in 11 patients being used to establish baseline dosage data.

Emyria Ltd has been awarded a grant of $499,411 to advance its MDMA analogue drug development program to treat a range of conditions.

Emyria's newly inaugurated Empax Centre has been selected as a key site for a clinical trial sponsored by New York-based Transcend Therapeutics.

Australian futures opened slightly down today, following European stocks which were down overnight on political tensions.

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair has funded the company $0.3M on Tuesday.

There's an emerging body of research suggesting the true value of psychedelics might be found in treating psychiatric conditions such as post-traumatic stress disorder (PTSD) and persistent depression.

Emyria Limited has opened the Empax Centre, a cutting-edge facility designed to advance innovative mental health treatments, including psychedelic-assisted therapies.

New studies have confirmed that medical cannabis helps relieve cancer pain, or side effects from cancer treatment.

The ASX has slogged its way to a fifth-straight drop, but a couple of tiny techies made waves as vitamin giant Blackmores ruled the roost.

The date April 20th has become an unofficial holiday among cannabis enthusiasts who now call it the World Marijuana Day.

Research finds finds most Australians are still medicating with illicit cannabis, although numbers accessing legal prescription have risen.

Paradigm Biopharma said that injectable pentosan polysulfate sodium (iPPS) may slow disease progression in knee osteoarthritis (OA).

The first of new products is set to be delivered by the end of FY23.

Overnight, US stocks plunged as the Fed pressed ahead with another 25bp hike (as expected), and signalled that rate-rising cycle is not done.

“In terms of stability, not all products containing CBD are created equal, and quality control can be a problem,” BOD MD Jo Patterson said.